ANTI-CD22 90y-epratuzumab tetraxetan combined with anti-cd20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-hodgkin lymphoma

Haematologica

Volumn 99, Issue 11, 2014, Pages 1738-1745

  Witzig, Thomas E ^a   Tomblyn, Michael B ^b   Misleh, Jamal G ^c   Kio, Ebenezer A ^d   Sharkey, Robert M ^e   Wegener, William A ^e   Goldenberg, David M ^e,f  

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c HELEN F GRAHAM CANCER CENTER   (United States)

^d INDIANA UNIVERSITY HEALTH   (United States)

^e Immunomedics   (United States)

^f CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPRATUZUMAB TETRAXETAN YTTRIUM Y 90; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VELTUZUMAB; ANTINEOPLASTIC AGENT; EPRATUZUMAB; INDIUM; MONOCLONAL ANTIBODY; YTTRIUM;

ARTICLE; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; IMMUNOGENICITY; LUNG INFILTRATE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; SCINTISCANNING; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; AGED; BONE MARROW; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DISEASE COURSE; FEMALE; HUMAN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE MARROW; DISEASE PROGRESSION; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84908410053     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.112110     Document Type: Article

References (41)

1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-26.
2. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma. 2010;51 (6):983-94.
3. Motta G1, Cea M, Moran E, Carbone F, Augusti V, Patrone F, Nencioni A. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol. 2010;2010:428253.
4. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011;25 (1):13-25.
5. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma 90Y-epratuzumab tetraxetan plus veltuzumab in NHL therapy. J Hematol Oncol. 2012; 5:64. doi: 10.1186/1756-8722-5-64
6. Press OW. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lym-phomas. J Clin Oncol. 2008;26(32):5147-50.
7. Ahmed S, Winter JN, Gordon LI, Evens AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma. 2010; 51(7):1163-77.
8. Illidge T, Morschhauser F. Radioimmu-notherapy in follicular lymphoma. Best Pract Res Clin Haematol. 2011; 24(2):279-93.
9. Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Cancer Control. 2012;19(3):196-203.
10. Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Faivre-Chauvet A, et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Front Oncol. 2013; 3:177.
11. Cessano A, Gayko, U, Braman C, Kapushoc H, Fields SZ, Perkins SL. Differential expression of CD22 in indolent and aggressive non-Hodgkin’s lymphoma (NHL): implications for targeted therapy. Blood. 2002;100 (Suppl):350a.
12. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6 (10):1341-53.
13. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lym-phoma. J Clin Oncol. 2003;21(16):3051-9.
14. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lym-phoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10(16):5327-34.
15. Shih LB, Lu HH, Xuan H, Goldenberg DM. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer. 1994;56(4):538-45.
16. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from ritux-imab. Mol Immunol. 2007;44(6):1331-41.
17. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997;44(3):179-88.
18. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003;44(1):77-84.
19. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44 (12):2000-18.
20. Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11(14): 5215-22.
21. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94(4 Suppl):1332-48.
22. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(23):3709-16.
23. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329(7):459-65.
24. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329(17):1219-24.
25. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2(3):457-70.
26. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase ½ study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113(7):1412-21.
27. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112(3):830-5.
28. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/ radioantibody therapy. Blood. 2009;113 (17):3891-5.
29. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman S, Hernandez-Ilizaliturri FJ. Properties and structure-function relationship of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113(5):1062-70.
30. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010;51(5):747-55.
31. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27(20):3346-53.
32. Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011;96(4):567-73.
33. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res. 2008;14 (19):6154-60.
34. Harris NL, Ferry JA. Classification of non-Hodgkin’s lymphomas. In: Knowles DM, ed. Neoplastic Hematopathology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 001. p. 691-753.
35. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94.
36. Cheson BD, Pfistner B, Juweid ME, E, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lym-phoma. J Clin Oncol. 2007;25(5):579-86.
37. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations, Revised Ed. New York, NY: The Society of Nuclear Medicine; 1991.
38. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34(4):689-94.
39. Kraeber-Bodéré F, Pallardy A, Soubeyran P, Bodet-Milin C, Garin E, Vuillez J-P, et al. Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y-epratuzumab tetraxetan following R-CHOP in elderly diffuse large B-cell lymphoma (DLBCL) patients. J Nucl Med. 2013;54(2 suppl):179.
40. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110(1):54-8.
41. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27(31):5213-8.